Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TAK-062 (PvP001/PvP002/PvP003) in Healthy Adults and Celiac Disease
NCT03701555Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jan 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zamaglutenase in celiac disease (5 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events and Percentage of Gluten Degradation. Started Jun 2018; status: completed.
02
Drugs
zamaglutenase
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT03701555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03701555.